410 related articles for article (PubMed ID: 18000219)
1. Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer.
Hosey AM; Gorski JJ; Murray MM; Quinn JE; Chung WY; Stewart GE; James CR; Farragher SM; Mulligan JM; Scott AN; Dervan PA; Johnston PG; Couch FJ; Daly PA; Kay E; McCann A; Mullan PB; Harkin DP
J Natl Cancer Inst; 2007 Nov; 99(22):1683-94. PubMed ID: 18000219
[TBL] [Abstract][Full Text] [Related]
2. Estrogen receptors in BRCA1-mutant breast cancer: now you see them, now you don't.
Jordan VC
J Natl Cancer Inst; 2007 Nov; 99(22):1655-7. PubMed ID: 18000213
[No Abstract] [Full Text] [Related]
3. BRD7, a subunit of SWI/SNF complexes, binds directly to BRCA1 and regulates BRCA1-dependent transcription.
Harte MT; O'Brien GJ; Ryan NM; Gorski JJ; Savage KI; Crawford NT; Mullan PB; Harkin DP
Cancer Res; 2010 Mar; 70(6):2538-47. PubMed ID: 20215511
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal Molecular Imaging of Progesterone Receptor Reveals Early Differential Response to Endocrine Therapy in Breast Cancer with an Activating
Kumar M; Salem K; Jeffery JJ; Yan Y; Mahajan AM; Fowler AM
J Nucl Med; 2021 Apr; 62(4):500-506. PubMed ID: 32859700
[TBL] [Abstract][Full Text] [Related]
5. ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2.
Pancholi S; Lykkesfeldt AE; Hilmi C; Banerjee S; Leary A; Drury S; Johnston S; Dowsett M; Martin LA
Endocr Relat Cancer; 2008 Dec; 15(4):985-1002. PubMed ID: 18824559
[TBL] [Abstract][Full Text] [Related]
6. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
[TBL] [Abstract][Full Text] [Related]
7. Silencing MED1 sensitizes breast cancer cells to pure anti-estrogen fulvestrant in vitro and in vivo.
Zhang L; Cui J; Leonard M; Nephew K; Li Y; Zhang X
PLoS One; 2013; 8(7):e70641. PubMed ID: 23936234
[TBL] [Abstract][Full Text] [Related]
8. The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells.
Ikeda H; Taira N; Hara F; Fujita T; Yamamoto H; Soh J; Toyooka S; Nogami T; Shien T; Doihara H; Miyoshi S
Breast Cancer Res; 2010; 12(3):R43. PubMed ID: 20579400
[TBL] [Abstract][Full Text] [Related]
9. Expression and regulation of estrogen receptor beta in human breast tumors and cell lines.
Vladusic EA; Hornby AE; Guerra-Vladusic FK; Lakins J; Lupu R
Oncol Rep; 2000; 7(1):157-67. PubMed ID: 10601611
[TBL] [Abstract][Full Text] [Related]
10. Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivin.
Vanderlaag KE; Hudak S; Bald L; Fayadat-Dilman L; Sathe M; Grein J; Janatpour MJ
Breast Cancer Res; 2010; 12(3):R32. PubMed ID: 20525379
[TBL] [Abstract][Full Text] [Related]
11. Alteration of Y-box binding protein-1 expression modifies the response to endocrine therapy in estrogen receptor-positive breast cancer.
Ito T; Kamijo S; Izumi H; Kohno K; Amano J; Ito K
Breast Cancer Res Treat; 2012 May; 133(1):145-59. PubMed ID: 21863258
[TBL] [Abstract][Full Text] [Related]
12. Wilms' tumor 1 suppressor gene mediates antiestrogen resistance via down-regulation of estrogen receptor-alpha expression in breast cancer cells.
Han Y; Yang L; Suarez-Saiz F; San-Marina S; Cui J; Minden MD
Mol Cancer Res; 2008 Aug; 6(8):1347-55. PubMed ID: 18708366
[TBL] [Abstract][Full Text] [Related]
13. Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation.
Lewis JS; Meeke K; Osipo C; Ross EA; Kidawi N; Li T; Bell E; Chandel NS; Jordan VC
J Natl Cancer Inst; 2005 Dec; 97(23):1746-59. PubMed ID: 16333030
[TBL] [Abstract][Full Text] [Related]
14. Differences in the transcriptional response to fulvestrant and estrogen deprivation in ER-positive breast cancer.
Patani N; Dunbier AK; Anderson H; Ghazoui Z; Ribas R; Anderson E; Gao Q; A'hern R; Mackay A; Lindemann J; Wellings R; Walker J; Kuter I; Martin LA; Dowsett M
Clin Cancer Res; 2014 Aug; 20(15):3962-73. PubMed ID: 24916694
[TBL] [Abstract][Full Text] [Related]
15. Effect of antiestrogens and aromatase inhibitor on basal growth of the human breast cancer cell line MCF-7 in serum-free medium.
Jensen J; Kitlen JW; Briand P; Labrie F; Lykkesfeldt AE
J Steroid Biochem Mol Biol; 2003 Mar; 84(4):469-78. PubMed ID: 12732292
[TBL] [Abstract][Full Text] [Related]
16. Estrogen-dependent sushi domain containing 3 regulates cytoskeleton organization and migration in breast cancer cells.
Moy I; Todorović V; Dubash AD; Coon JS; Parker JB; Buranapramest M; Huang CC; Zhao H; Green KJ; Bulun SE
Oncogene; 2015 Jan; 34(3):323-33. PubMed ID: 24413080
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia reduces hormone responsiveness of human breast cancer cells.
Kurebayashi J; Otsuki T; Moriya T; Sonoo H
Jpn J Cancer Res; 2001 Oct; 92(10):1093-101. PubMed ID: 11676860
[TBL] [Abstract][Full Text] [Related]
18. Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions.
Wen J; Li R; Lu Y; Shupnik MA
Oncogene; 2009 Jan; 28(4):575-86. PubMed ID: 18997820
[TBL] [Abstract][Full Text] [Related]
19. Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor alpha to vinblastine and vinorelbine.
Sui M; Jiang D; Hinsch C; Fan W
Breast Cancer Res Treat; 2010 Jun; 121(2):335-45. PubMed ID: 19626437
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of IRS1 Enhances IGF1 Response in Y537S and D538G ESR1 Mutant Breast Cancer Cells.
Li Z; Levine KM; Bahreini A; Wang P; Chu D; Park BH; Oesterreich S; Lee AV
Endocrinology; 2018 Jan; 159(1):285-296. PubMed ID: 29029116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
